dChan
Anonymous ID: f2410f April 7, 2020, 1:58 p.m. No.8715469   🗄️.is 🔗kun   >>5567 >>5815 >>5953

DeBartolo Family Donates $7.65M to Tampa General Hospital

The generous donation will help support COVID-19 relief efforts, hospital programming and technology

 

https://www.prnewswire.com/news-releases/debartolo-family-donates-7-65m-to-tampa-general-hospital-301037071.html

 

TAMPA, Fla., April 7, 2020 /PRNewswire/ – Eddie and Candy DeBartolo have generously donated $7.65M to Tampa General Hospital over the course of five months. This week, the DeBartolo family donated $2.5M to Tampa General Hospital to help treat patients in the Tampa Bay area diagnosed with infectious diseases including COVID-19. The funds will be used to develop a long-term dedicated COVID-19 unit that would provide a dedicated area to diagnose and treat community members. This will also help pay for the construction and equipment, including necessary negative pressure isolation rooms and ventilators. A timeline for opening has not yet been set.

Anonymous ID: f2410f April 7, 2020, 2:29 p.m. No.8715687   🗄️.is 🔗kun

https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-daily-roundup-301037109.html

Today, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg. for the treatment of: (1) Uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax. (2) Chronic discoid lupus erythematosus and systemic lupus erythematosus in adults and (3) Treatment of acute and chronic rheumatoid arthritis in adults. Side effects of hydroxychloroquine include irreversible retinal damage, cardiac effects (including cardiomyopathy and QT prolongation), worsening of psoriasis and porphyria, proximal myopathy and neuropathy, neuropsychiatric events, and hypoglycemia. The FDA recently posted information regarding shortages of hydroxychloroquine and chloroquine to its drug shortages webpage due to a significant surge in demand. The agency is working with manufacturers to assess their supplies and is actively evaluating market demand for patients dependent on hydroxychloroquine and chloroquine for treatment of malaria, lupus and rheumatoid arthritis